AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given PO or IV
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT05564377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study NCT05564377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selumetinib Sulfate
Description: Given PO
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Given PO
Study NCT05564377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotorasib
Description: Given PO
Study NCT05047172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor + Aspirin
Description: ticagrelor (180 mg loading dose, then 90mg twice daily) and aspirin (81mg daily)
Study NCT06187090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form
Description: Um-PEA is to be taken orally once a day (600 mg per day) around mealtime during the 12-week initial phase of the study. During the 24-week extension phase of the study, the trial medication is to be taken from once a day up to twice a day (600-1200 mg per day), based on clinical judgment of the improvement obtained so far, around mealtime.
Study NCT06410235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation and exercise program
Description: The group received exercises and manipulation with physiotherapist follow-up for eight weeks and thoracic manipulation was performed once a week.
Study NCT06410235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise program
Description: The group received exercise
Study NCT05828394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DFGG
Description: Depithelised free gingival graft harvesting technique
Study NCT05828394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCTG
Description: Subepithelial connective tissue graft harvesting technique
Study NCT05047172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban + Aspirin
Description: low dose rivaroxaban (2.5mg twice daily) and aspirin (81mg daily)
Study NCT05047172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel + Aspirin
Description: clopidogrel (600mg loading dose, then 75mg daily) and aspirin (81mg daily)
Study NCT05047172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk Factor Management
Description: Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed.
Study NCT05047172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Risk Factor Management
Description: Risk factors for stroke (LDL, blood pressure, non-HDL cholesterol, diabetes, smoking, weight, and physical activity) will be monitored and managed.
Study NCT06203600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo optional blood sample collection
Study NCT06203600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo optional blood sample collection
Study NCT06203600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06203600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06203600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06203600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06203600 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT06203600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT06203600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT06203600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06203600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06203600 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Given IV
Study NCT06203600 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Given IV
Study NCT05013957 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Methylation analysis
Description: Methylation analysis
Study NCT03913117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pNGVL4aCRTE6E7L2
Description: Naked pNGVL4aCRTE6E7L2 DNA plasmid
Study NCT03913117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TA-CIN
Description: TA-CIN is a single fusion protein comprised of HPV16 L2, E7 and E6 proteins linked in tandem.
Study NCT06643793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome (ll) + 5-FU/LV + bevacizumab
Description: 1. Bevacizumab: 5 mg/kg, d1, q2w;~2. Irinotecan Hydrochloride Liposomal Injection (II): 60 mg/m2, d1, q2w;~3. leucovorin: 400 mg/m2, d1, q2w;~4. 5-fluorouracil: 2800 mg/m2, d1, q2w.
Study NCT05255172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise
Description: 12 weeks of supervised aerobic exercise individually adapted to exercise capacity according to a VO2 peak test
Study NCT04771442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stromal vascular fraction
Description: Single dose
Study NCT04860453 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: WES via Illumina NextSeq 550 sequencing system
Description: Sequencing will be performed on an Illumina sequencing system
Study NCT04860453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Blood draw will be via any University Hospitals Laboratory site and sent at room temperature via courier to the Center for Human Genetics (CHG) Laboratory
Study NCT04860453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood Draw
Description: Blood draw will be via any University Hospitals Laboratory site and sent at room temperature via courier to the Center for Human Genetics (CHG) Laboratory
Study NCT04860453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Skin samples obtained via 3mm punch biopsy will be suspended in cell culture media prepared per CHG routine and sent via courier to the Center for Human Genetics Laboratory
Study NCT04860453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Skin samples obtained via 3mm punch biopsy will be suspended in cell culture media prepared per CHG routine and sent via courier to the Center for Human Genetics Laboratory
Study NCT04860453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Saliva Sample
Description: Participant will provide a saliva sample which be shipped to University Hospitals Laborator site at room temperature
Study NCT04860453 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Saliva Sample
Description: Participant will provide a saliva sample which be shipped to University Hospitals Laborator site at room temperature
Study NCT06643897 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative Interview
Description: 40-50 minute-qualitative interview.
Study NCT06565442 — intervention group
Intervention type: DEVICE
Intervention: NeuraSignal transcranial doppler robot
Description: measure cerebral blood flow correlated with arterial blood pressure to generate individualized cerebral autoregulatory curves
Study NCT05627258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB0115-00-AB
Description: VRC01.23LS is a broadly neutralizing monoclonal antibody that targets the CD4 binding site in the HIV-1 envelope, is human in origin, and contains two amino acid modifications within the C-terminus of the heavy chain constant region designed to improve antibody half-life in vivo.
Study NCT04801225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive electromagnetic stimulation for acute stroke treatment
Description: Bilateral electromagnetic stimulation to improve blood flow in ischemic regions of acute stroke as an adjunct to current standard-of-care
Study NCT06576765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0780
Description: Dose 1
Study NCT04532047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldurazyme (laronidase)
Description: Enzyme replacement therapy for lysosomal storage diseases
Study NCT06058377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo optional collection of tissue and/or blood
Study NCT06058377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo optional collection of tissue and/or blood
Study NCT06058377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT06058377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT06058377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Given IV
Study NCT06058377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT06058377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT06058377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Undergo MammaPrint testing
Study NCT06058377 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mammography
Description: Undergo mammography
Study NCT06058377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mammography
Description: Undergo mammography
Study NCT06058377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT06058377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT06058377 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06058377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06066138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab administered via IV at either 1,200 mg q3 weeks, or 1,680 mg q4 weeks for the first 2 doses followed by 840mg q2 weeks or q6 weeks.
Study NCT05578300 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombus analyses
Description: Physical, histology, biochemical or protein expressions of the thrombi obtained from thrombectomy procedures may contain information regarding the etiology of stroke and relevant disease pathology. The investigators shall store the thrombus, if any, yielded from thrombectomy procedures for future analyses.
Study NCT05578300 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging assessment
Description: All imaging data will be deidentified before assessment. Plain computer tomography of the brain (CT brain), CT angiography (CTA), CT perfusion (CTP), magnetic resonance imaging of the brain (MRI), digital subtraction imaging (DSA) will be analysed. The investigators shall blind the assessors from treatment choice and outcome in all analyses that require human assessment.
Study NCT05932485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate nerve block
Description: Before the operation, the left stellate ganglion block was performed, and 0.375% ropivacaine 5ml was injected into the stellate ganglion.
Study NCT05523869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal topotecan
Description: Patients meeting all inclusion criteria and not meeting exclusion criteria will be assigned to receive pars plana vitrectomy with or without scleral buckle with intravitreal topotecan 8 µg/0.1mL, administered preoperatively within one week from surgery, intraoperatively during surgery, as well as postoperatively at 2 weeks, 4 weeks, 8 weeks, 12 weeks and 16 weeks, for a total of 7 injections.
Study NCT05523869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with or without scleral buckle
Description: Standard three-port pars plana vitrectomy with or without scleral buckle.
Study NCT05523869 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy with or without scleral buckle
Description: Standard three-port pars plana vitrectomy with or without scleral buckle.
Study NCT04972682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node biopsy
Description: Laparoscopic total hysterectomy, bilateral salpingo-oophorectomy (BSO), and sentinel lymph node (SLN) biopsy are executed by 1 of 5 experienced gynecologic oncologists. SLN mapping utilizes indocyanine green (ICG) at a standard concentration of 2.5 mg/mL - 1 mL is injected into the cervix at the 3 and 9 o'clock positions (total dose - 5 mg) to a depth of 5-10 mm, initiated right after general anesthesia induction. Diagnostic laparoscopy employs the Image 1S equipment (KARL STORZ©, Tuttlingen, Germany). Upon examination, fluorescence in the near-infrared spectrum is observed. Successful mapping is indicated by identifying a lymphatic vessel with at least one LN. Detected SLNs are then extracted, and the total hysterectomy with BSO is completed. SLN frozen section remains at the surgeon's discretion. If metastasis surfaces in the SLN either during the frozen section or routine assessment, the option for systematic LN dissection in a subsequent procedure exists although not mandatory.
Study NCT05058690 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test
Description: * Obtain blood sample for glucose assessment (time 0 sample). This may be obtained via venepuncture or after cannula insertion.~* Test a small sample using a near patient glucose testing meter. If the result on the glucose meter is greater than or equal to 11mmol/L, send the blood sample urgently to lab. If it is confirmed by biochemistry to be above 11mmol/L, there is no need to continue test.~* If the result is less than 11mmol/L on meter, give the patient the glucose solution to drink.~* Collect a further blood sample at 120 minutes.~* Send samples all together to laboratory for glucose measurement.
Study NCT05481905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENX-101
Description: Adjunctive treatment to current antiseizure medication
Study NCT05481905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ENX-101
Description: Adjunctive treatment to current antiseizure medication
Study NCT05940363 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Improvement on Prenatal Screening and Treatment Capabilities for Congenital Heart Disease with a Comprehensive Diagnosis and Treatment Program Incorporating New Technologies
Description: To investigate and evaluate the capacity of prenatal screening, diagnosis and counseling for fetal heart disease based on medical institutions; Improving capacity for prenatal screening, diagnosis and counselling through integrated products embedded with new technologies.
Study NCT06100848 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Microbiological analysis after Caries treatment
Description: Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 40 minutes later.
Study NCT06100848 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Microbiological analysis after Caries treatment and fumigation
Description: Microbiological analysis was conducted for 30 patients using 30 microbiological plates. These plates were opened simultaneously with the start of the treatment and closed 60 minutes later (when fumigation was finished)
Study NCT05554328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT06303375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Kinesiotaping using inhibition technique in tight muscles and facilitation technique in weak muscles for LCS. Treatment sessions 3 days per week for almost 04 weeks.~10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week
Study NCT05554328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT06303375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy
Description: 10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week
Study NCT05554328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection
Study NCT05554328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood collection
Study NCT05554328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration or biopsy
Study NCT05554328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration or biopsy
Study NCT06303375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: 10 mins moist hot pack~* Stretching exercises of tight erector spinae, hip flexors 3-4 times a week 5 sec hold 5-7 reps 1 set.~* Strengthening of weak abdominals and gluteal muscles 2-3 times in a week
Study NCT05554328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05554328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05554328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT05554328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT05554328 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT05554328 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT05554328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT05554328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO
Study NCT05554328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selumetinib Sulfate
Description: Given PO
Study NCT06427798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE
Description: 68Ga-DOTATATE PET/CT whole-body scanning will be done at target dose of 5 mCi. The whole-body PET/CT scan will be started approximately 60 minutes after the tracer injection and will take up to 2 hours.
Study NCT06427798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [203Pb]VMT-alpha-NET
Description: \[203Pb\]VMT-alpha-NET (6 mCi) will be given IV at 7 days prior.
Study NCT06427798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [212Pb]VMT-alpha-NET
Description: \[212Pb\]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during Phase II. One cycle is 8 weeks.
Study NCT05309200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCE-205
Description: The drug product, OCE-205, is a sterile solution to be used for intravenous infusion.